Skip to the main content.

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

As we continue to explore the world of cell and gene therapy, we now take a look at managing costs and scale up risks for medical devices.

Author Dave Seward, discusses how the principles of Quality by Design (QbD) and Design for Manufacture (DfM) can be applicable to ATMPs. Read this blog now!

Driving excellence in aseptic fill-finish: Our strategic partnership with Stäubli Robotics

Driving excellence in aseptic fill-finish: Our strategic partnership with Stäubli Robotics

At 3P innovation, we engineer automation with purpose - solutions that don’t just meet the demands of aseptic manufacturing but redefine what’s...

Read More
Custom pharmaceutical extrusion: powering the next generation of drug delivery systems

Custom pharmaceutical extrusion: powering the next generation of drug delivery systems

Pharmaceutical extrusion is a critical enabler in the manufacture of advanced drug delivery systems, from long-acting injectables to solid implants....

Read More
Responding to cell & gene fill-finish and automation scale-up challenges

Responding to cell & gene fill-finish and automation scale-up challenges

Before delving into some technical details of cell and gene therapy manufacturing, it’s worth pausing to reflect on the human stories that drive this...

Read More